Kenya Association of Physicians Scientific Conference

Permanent URI for this collection

https://hdl.handle.net/1805/1156

Browse

Recent Submissions

Now showing 1 - 10 of 24
  • Thumbnail Image
    Item
    Acute Myeloid Leukemia: The Aga Khan Experience
    (Association of Kenya Physicians, 2007) Ngunga, Mzee; Association of Kenya Physicians Scientific Conference (11th : Mar. 2007 : Eldoret, Kenya)
    AML is characterized by an increase in the number of myeloid cells in the marrow and an arrest in their maturation.
  • Thumbnail Image
    Item
    Chemotherapy-Related Tumour Lysis Syndrome
    (Association of Kenya Physicians, 2007) Busakhala, N. W.; Association of Kenya Physicians Scientific Conference (11th : Mar. 2007 : Eldoret, Kenya)
    Two types of tumour lysis syndrome (TLS) ; 1. Laboratory TLS: 25% increase in potassium, phosphate and uric acid, or decline in calcium from baseline. Occur within 4 days of initiating chemotherapy. Patients on standard of care. Minimum of two out of four criteria. 2. Clinical tumour lysis syndrome: Laboratory TLS plus renal failure, cardiac arrhythmias or sudden death. A new definition has been suggested by Cairo and Bishop to include values above upper limit of normal. Study used Hande and Garrow definition.
  • Thumbnail Image
    Item
    Renal Transplant at MTRH
    (Association of Kenya Physicians, 2007) Owiti, M. O. G.; Association of Kenya Physicians Scientific Conference (11th : Mar. 2007 : Eldoret, Kenya)
    J.A. 48 yrs male - Diabetic since July 1997, on insulin. Crf & high Bp-2004.urea=57.3, crt=1040. Lt kid-7.27x3.62, rt kid8.51x3.34cm, loss of cmd. Haemodialysis x2 wkly till last two wksx3. While on treatment Bp=150/100, pulse78/min. on Adalat 20mg b.d,lasix 80mg od, captopril 25mg b.d,ca-sandoz i.o.d, recormon 2000i.u x2wkly, venofer 100 wkly, ranitidine150 mgo.d. N.C. 17 yrs female - Facial puff, head ache,oliguria, epigastric and bil loin Painsx3/52. 03.08.2004. Post herbal use. Abortion –pph, 07.06.04, post abortal psychosis. Bp220/110mmhg, hb=7.6g/dl, Op=600mls, ip=1.5l.
  • Thumbnail Image
    Item
    Health Care Today Good Business Bad Medicine
    (Association of Kenya Physicians, 2007) Aluoch, J. A.; Association of Kenya Physicians Scientific Conference (11th : Mar. 2007 : Eldoret, Kenya)
    HEALTH CARE TODAY • POLITICAL INFLUENCE. • EXPANDING SERVICES • QUALITY OF CARE. • PRIVATE CARE Vs PUBLIC SERVICE.
  • Thumbnail Image
    Item
    Disparities of Health Care: Challenge to Physicians
    (Association of Kenya Physicians, 2007) Nyikal, James; Association of Kenya Physicians Scientific Conference (11th : Mar. 2007 : Eldoret, Kenya)
    Challenges to the health sector: Finance and financial flows. Rapid growth of infrastructure. Human resource. Emerging diseases. Coordination. Legal framework. Poverty. Challenges to the physician: Health reforms. Leadership role and head of team. Role model. Cost of care and poverty. Ethics in compromised social environment. CPD. Curative care/disease prevention and health promotion. Perpetual dilemma.
  • Thumbnail Image
    Item
    Dr. Abinya's Hodgkin's lymphoma study
    (Association of Kenya Physicians, 2007) Abwao, H. O.; Kiarie, G.W.; Othieno-Abinya, N. A.; Association of Kenya Physicians Scientific Conference (11th : Mar. 2007 : Eldoret, Kenya)
    Inferior outcome of poor prognostic phenotype non-Hodgkin’s lymphoma treatment among HIV positive patients compared with HIV negative counterparts in the HAART era.
  • Thumbnail Image
    Item
    The ACT Malaria Treatment Policy Change in Kenya
    (Association of Kenya Physicians, 2007) Akhwale, Willis S.; Association of Kenya Physicians Scientific Conference (11th : Mar. 2007 : Eldoret, Kenya)
    Objectives of the national Antimalarial treatment policy: •Enable population at risk access safe, good quality, effective, affordable & acceptable antimalarial drugs •Ensure rapid and long lasting clinical cure •Prevent progression to severe disease •Reduce the incidence of anaemia •Reduce consequences of placental malaria infection •Delay development of resistance to antimalarial drugs Key specific issues: •Limited data available on safety of ACTs in young infants (use of coartem <5kgs) •Lack of adequate safety and efficacy data on drug combinations in pregnant women (safety of lumefantrine in pregnancy) •Improving systems of forecasting of drug needs •Strengthening the management and drug supply system (procurement, distribution and use) according to the specificities of the new drugs (shorter shelf life and the course-of-therapy packs) •Complex treatment schedules poses challenge for ensuring compliance •Need for more friendly paediatric formulations
  • Thumbnail Image
    Item
    Combination of OHA Therapy in Type 2 Diabetes Mellitus
    (Association of Kenya Physicians, 2007) Shah, Siddharth; Association of Kenya Physicians Scientific Conference (11th : Mar. 2007 : Eldoret, Kenya)
    O.H.A. are the most common form of treatment of Type2 D.M. worldwide. When used judiciously they are important agents in the management of the most common form of diabetes. For economic, logistic and general effectiveness, oral agents are a dependable means of treating a large population of diabetics worldwide when used correctly.
  • Thumbnail Image
    Item
    Management of Arthritis
    (Association of Kenya Physicians, 2007) Association of Kenya Physicians Scientific Conference (11th : Mar. 2007 : Eldoret, Kenya)
  • Thumbnail Image
    Item
    Slowing Disease Progression in Type 2 Diabetes: Latest Advances
    (Association of Kenya Physicians, 2007) Otieno, C. F.; Association of Kenya Physicians Scientific Conference (11th : Mar. 2007 : Eldoret, Kenya)
    Background: Largest head-to-head, double-blind study of metformin, glyburide and rosiglitazone (N = 4,360). Primary objective: To compare the durability of glycemic control using rosiglitazone versus metformin or glyburide as initial monotherapy in patients with recently diagnosed type 2 diabetes. Design: Double-blind, randomized, controlled trial. Inclusion criteria: Type 2 diabetes ≤ 3 years, drug-naive, male and female, aged 30–75 years, FPG 126–180 mg/dl (7–10 mmol/l). Exclusion criteria: Previous use of glucose-lowering therapy, women of child-bearing potential, significant hepatic disease, renal impairment, unstable or severe angina, known CHF (NYHA Class I–IV), uncontrolled hypertension. Treatment duration: Treatment period: 4 to 6 years. Median duration of treatment: 4 years (rosiglitazone and metformin); 3.3 years (glyburide). Interventions: Rosiglitazone, metformin, glyburide.